Arrowhead Announces Pricing Of A Public Offering Of Common Stock And Warrants

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has priced a public offering of approximately 1.65 million units at a price to the public of $2.12 per unit. The Company has received commitments for approximately $3.5 million in gross proceeds. The sale of the units is expected to close on or about January 30, 2013, subject to the satisfaction of customary closing conditions. Each unit consists of one share of common stock and one warrant to purchase 0.50 of a share of common stock.

Arrowhead intends to use the net proceeds of this offering for general corporate purposes, including working capital, research and development expenditures, clinical trial expenditures, and capital expenditures.

Dawson James Securities, Inc. is acting as the sole book-running manager for the offering. The shares of common stock and warrants will be issued separately, and no units will be issued or certificated. The warrants are exercisable immediately upon issuance, have a five-year term and an exercise price of $2.14 per share. The warrants will be delivered to the investors by physical delivery following the closing. There is no established public trading market for the warrants and we do not expect a market to develop.

The securities described above are being offered pursuant to an effective registration statement on Form S-3, together with a prospectus supplement and accompanying base prospectus, previously filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement relating to the terms of the offering has been filed with the SEC and is available on the SEC’s web site at http://www.sec.gov. Copies of the final prospectus supplement relating to the offering, when available, may be obtained from Dawson James Securities, Inc., 925 South Federal Highway, 6th Floor, Boca Raton, FL 33432 or via telephone at (866) 928-0928 or via e-mail at placements@djsiny.com, or from the above-mentioned SEC website.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

If you liked this article you might like

Take a Look at These Stocks Poised to Trade Higher

These 5 Stocks Under $10 Could Explode Higher

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

The Worst Biopharma CEOs of 2016 Are ...